# Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

> **NCT04332666** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Erasme University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Coronavirus
- Respiratory Failure
- Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
- SARS-CoV-2

## Interventions

- **DRUG:** Angiotensin 1-7
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04332666
- **Lead sponsor:** Erasme University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-30
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04332666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04332666, "Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04332666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*